F. von Nussbaum

发表

Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.

H. Briem, P. Lienau, M. Schäfer, 2021, Journal of medicinal chemistry.

Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.

F. Prinz, D. Suelzle, B. Nicke, 2019, Journal of medicinal chemistry.

BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models

Andreas Hägebarth, Ningshu Liu, O. Politz, 2017, International journal of cancer.

Lost in transcription--inhibition of RNA polymerase.

F. von Nussbaum, D. Haebich, 2009, Angewandte Chemie.

Structure and total synthesis of lysobactin (katanosin B).

N. Brunner, J. Benet‐Buchholz, J. Köbberling, 2007, Angewandte Chemie.

Multiple attack on bacteria by the new antibiotic teixobactin.

R. Süssmuth, F. von Nussbaum, 2015, Angewandte Chemie.

Frontiers in Medicinal Chemistry 2022 Goes Virtual

Franca-Maria Klingler, M. Jung, M. Gehringer, 2022, ChemMedChem.

Antibacterial natural products in medicinal chemistry--exodus or revival?

Stefan Weigand, Michael Brands, B. Hinzen, 2006, Angewandte Chemie.

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

H. Briem, P. Lienau, P. Nussbaumer, 2017, ChemMedChem.

An Iron(III)-Catechol Complex as a Mushroom Pigment.

L. Stievano, G. Wanner, P. Spiteller, 1998, Angewandte Chemie.

Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524

E. Nigg, G. Siemeister, Conrad von Schubert, 2016, eLife.

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.

H. Briem, P. Lienau, U. Klar, 2020, Journal of medicinal chemistry.

Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

H. Briem, O. von Ahsen, G. Siemeister, 2018, Clinical Cancer Research.

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity

P. Lienau, O. von Ahsen, U. Klar, 2016, Molecular Cancer Therapeutics.

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models

Clara D. Christ, E. Nevedomskaya, H. Briem, 2021, Cellular Oncology.

BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients

C. Stephan, K. Jung, B. Haendler, 2016, Oncotarget.

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction

H. Briem, G. Siemeister, D. Moosmayer, 2019, Proceedings of the National Academy of Sciences.

BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity.

P. Lienau, D. Mumberg, C. Lange, 2017, Cancer letters.

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models

Clara D. Christ, E. Nevedomskaya, H. Briem, 2021, Cellular Oncology.

Discovery of BAY-985 a highly selective TBK1/Ikkε inhibitor.

F. Prinz, H. Briem, D. Panne, 2019, Journal of medicinal chemistry.

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

A. Schlicker, P. Lienau, B. Haendler, 2019, Molecular Cancer Therapeutics.

Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A.

Clara D. Christ, B. Nicke, P. Lienau, 2021, Journal of medicinal chemistry.

Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores.

V. Li, F. von Nussbaum, 2015, Bioorganic & medicinal chemistry letters.

Aspergillomarasmine A, an inhibitor of bacterial metallo-β-lactamases conferring blaNDM and blaVIM resistance.

G. Schiffer, F. von Nussbaum, Guido Schiffer, 2014, Angewandte Chemie.

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.

H. Briem, P. Lienau, U. Luecking, 2020, Journal of medicinal chemistry.

Synthesis of 1-(2-aminophenyl)isoquinolines and the biological activity of their cis-dichloro platinum(II) complexes.

S. Wild, H. Zorbas, W. Steglich, 1999, Journal of medicinal chemistry.

Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524

E. Nigg, G. Siemeister, Conrad von Schubert, 2016, eLife.

European Medicinal Chemistry Leaders in Industry (EMCL) – On the Status and Future of Medicinal Chemistry Research in Europe **

A. Torrens, M. Bossart, Michael Wagner, 2023, ChemMedChem.

Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.

A. Schlicker, P. Lienau, L. Potze, 2024, Cell chemical biology.